Clinical and Translational Oncology

, Volume 14, Issue 5, pp 391–395 | Cite as

Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma

  • Kyubo Kim
  • Eui Kyu ChieEmail author
  • Jin-Young Jang
  • Sun Whe Kim
  • Sae-Won Han
  • Do-Youn Oh
  • Seock-Ah Im
  • Tae-You Kim
  • Yung-Jue Bang
  • Sung W. Ha
Research Articles



To analyse the outcome of adjuvant chemoradiotherapy for periampullary adenocarcinoma and the impact of tumour location as a prognosticator.

Methods and materials

Between January 1991 and December 2002, 147 patients with periampullary cancer underwent adjuvant chemoradiotherapy after pancreaticoduodenectomy. Postoperative radiotherapy was delivered to tumour bed and regional lymph nodes up to 40 Gy at 2 Gy/fraction with a two-week planned rest. Intravenous 5-fluorouracil (500 mg/m2/day) was given on days 1–3 of each split course. The median follow-up period was 82 months in survivors.


Tumour >2 cm and margin-positivity were more common in patients with pancreatic cancer than nonpancreatic periampullary cancers (p<0.0001 and 0.0780, respectively). According to the tumour location, 5-year overall survival rates of ampulla of Vater, distal common bile duct, duodenal and pancreatic head cancers were 53.0%, 50.3%, 37.5%, and 13.0%, respectively (p<0.0001). On multivariate analysis, pancreatic location (p<0.0001) and nodal involvement (p=0.0123) were associated with inferior overall survival.


Regardless of its advanced histologic features, pancreatic location itself was an adverse prognostic factor affecting overall survival.


Periampullary adenocarcinoma Adjuvant chemoradiotherapy Pancreas Location 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yeo CJ, Cameron JL, Sohn TA et al (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Ann Surg 226:248–260PubMedCrossRefGoogle Scholar
  2. 2.
    Connolly MM, Dawson PJ, Michelassi F et al (1987) Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 206:366–373PubMedCrossRefGoogle Scholar
  3. 3.
    Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006–2010CrossRefGoogle Scholar
  4. 4.
    Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776–782PubMedCrossRefGoogle Scholar
  5. 5.
    Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210PubMedCrossRefGoogle Scholar
  6. 6.
    Bouvet M, Gamagami RA, Gilpin EA et al (2000) Factors influencing survival after resection for periampullary neoplasms. Am J Surg 180:13–17PubMedCrossRefGoogle Scholar
  7. 7.
    Schmidt CM, Powell ES, Yiannoutsos CT et al (2004) Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 139:718–727PubMedCrossRefGoogle Scholar
  8. 8.
    de Castro SM, Kuhlmann KF, van Heek NT et al (2004) Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg 8:775–784PubMedCrossRefGoogle Scholar
  9. 9.
    Lee JH, Whittington R, Williams NN et al (2000) Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 47:945–953PubMedCrossRefGoogle Scholar
  10. 10.
    Mehta VK, Fisher GA, Ford JM et al (2001) Adjuvant chemoradiotherapy for “unfavorable” carcinoma of the ampulla of Vater. Arch Surg 136: 65–69PubMedCrossRefGoogle Scholar
  11. 11.
    Kim K, Chie EK, Jang JY et al (2009) Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys 75:436–441PubMedCrossRefGoogle Scholar
  12. 12.
    Serafini FM, Sachs D, Bloomston M et al (2001) Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 67:839–844PubMedGoogle Scholar
  13. 13.
    Kim K, Chie EK, Jang JY et al (2010) Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer? Int J Radiat Oncol Biol Phys 77:1186–1190PubMedCrossRefGoogle Scholar
  14. 14.
    Kaplan EL, Meier PI (1958) A nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
  15. 15.
    Katz MH, Bouvet M, Al-Refaie W et al (2004) Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis. Hepatogastroenterology 51:842–846PubMedGoogle Scholar
  16. 16.
    Yeo CJ, Sohn TA, Cameron JL et al (1998) Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227:821–831PubMedCrossRefGoogle Scholar
  17. 17.
    Jarufe NP, Coldham C, Mayer AD et al (2004) Favorable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region. Dig Surg 21: 202–209PubMedCrossRefGoogle Scholar
  18. 18.
    Abrams RA, Grochow LB, Chakravarthy A et al (1999) Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 44:1039–1046PubMedCrossRefGoogle Scholar
  19. 19.
    Chakravarthy A, Abrams RA, Yeo CJ et al (2000) Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys 48:1089–1096PubMedCrossRefGoogle Scholar
  20. 20.
    Breslin TM, Hess KR, Harbison DB et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132PubMedCrossRefGoogle Scholar
  21. 21.
    Regine WF, Abrams RA (1998) Adjuvant therapy for pancreatic cancer: back to the future. Int J Radiat Oncol Biol Phys 42:59–63PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2012

Authors and Affiliations

  • Kyubo Kim
    • 1
  • Eui Kyu Chie
    • 1
    Email author
  • Jin-Young Jang
    • 2
  • Sun Whe Kim
    • 2
  • Sae-Won Han
    • 1
    • 3
  • Do-Youn Oh
    • 3
  • Seock-Ah Im
    • 3
  • Tae-You Kim
    • 3
  • Yung-Jue Bang
    • 3
  • Sung W. Ha
    • 4
  1. 1.Department of Radiation OncologySeoul National University College of MedicineSeoulRepublic of Korea
  2. 2.Department of SurgerySeoul National University College of MedicineSeoulRepublic of Korea
  3. 3.Department of Internal MedicineSeoul National University College of MedicineSeoulRepublic of Korea
  4. 4.Institute of Radiation Medicine Medical Research CenterSeoul National UniversitySeoulRepublic of Korea

Personalised recommendations